Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Short Communication

The Impact of COVID-19 Lockdown on Patients with Type 2 Diabetes Mellitus: A Brief Report

Author(s): Alfredo Vozza, Erasmo Porfido, Alessandra Delvino, Carlo Custodero, Giuseppe Lisco*, Vincenzo Triggiani, Cosimo Tortorella and Giuseppina Piazzolla

Volume 23, Issue 8, 2023

Published on: 09 March, 2023

Page: [1041 - 1045] Pages: 5

DOI: 10.2174/1871530323666230112165948

Price: $65

Abstract

Background: The Italian population’s habits changed dramatically during the “COVID- 19 lockdown” due to physical distancing and self-isolation. Moreover, medical consultations of patients with chronic diseases, such as type 2 diabetes (T2D), were suspended or postponed, unless urgent or semi-urgent, for several consecutive months. Thus, it is expected that the lockdown could have affected glucometabolic control in T2D. v

Purpose: The aim of the study was to assess changes in glucometabolic control in a cohort of T2D patients before (T1) and after (T2) the COVID-19 lockdown (March-May 2020).

Methods: The study was approved by the Ethics Committee of the University of Bari, and all patients provided informed written consent to participate. Medical history, complete physical examination, and laboratory assessment were conducted as real-life clinical practice. Changes in clinical and laboratory variables between T1 and T2 were calculated.

Results: In detail, 13 patients were on metformin as monotherapy, 36 on GLP-1RA, 12 on sodiumglucose transporter 2 inhibitors (SGLT-2i), and 2 on dipeptidyl-peptidase 4 inhibitors (DPP4i). The mean age was 65.3 years (43-83). Study participants were mainly men (73%). The body weight (BW) ranged from 56 to 145 kg, and the waist circumference ranged from 88 to 146 cm. The mean HbA1c was 51.0 mmol/mol. At T2, no statistically significant changes were observed frombaseline except for BW [-1.6 (-2.60 to -0.62)] and HbA1c [-2.90 (-4.69; -1.12)].

Conclusion: We evaluated the effects of the COVID-19 lockdown on glucometabolic control in patients with background well-controlled T2D. We found that the lockdown had no adverse effects on metabolic profile regardless of background clinical characteristics and antihyperglycemic management. Despite limitations due to the nature of this study (sample size, retrospective observation, lack of data on lifestyle changes in our patients' everyday lives), T2D patients managed in our Diabetes Centers faced the lockdown-related restrictions without any detrimental consequence.

« Previous Next »
Graphical Abstract

[1]
Zhang, W.; Zhao, Y.; Zhang, F.; Wang, Q.; Li, T.; Liu, Z.; Wang, J.; Qin, Y.; Zhang, X.; Yan, X.; Zeng, X.; Zhang, S. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin. Immunol., 2020, 214108393
[http://dx.doi.org/10.1016/j.clim.2020.108393] [PMID: 32222466]
[2]
Di Renzo, L.; Gualtieri, P.; Pivari, F.; Soldati, L.; Attinà, A.; Cinelli, G.; Leggeri, C.; Caparello, G.; Barrea, L.; Scerbo, F.; Esposito, E.; De Lorenzo, A. Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey. J. Transl. Med., 2020, 18(1), 229.
[http://dx.doi.org/10.1186/s12967-020-02399-5] [PMID: 32513197]
[3]
Zupo, R.; Castellana, F.; Sardone, R.; Sila, A.; Giagulli, V.A.; Triggiani, V.; Cincione, R.I.; Giannelli, G.; De Pergola, G. Preliminary trajectories in dietary behaviors during the COVID-19 pandemic: A public health call to action to face obesity. Int. J. Environ. Res. Public Health, 2020, 17(19), 7073.
[http://dx.doi.org/10.3390/ijerph17197073] [PMID: 32992623]
[4]
De Nucci, S.; Zupo, R.; Castellana, F.; Sila, A.; Triggiani, V.; Lisco, G.; De Pergola, G.; Sardone, R. Public health response to the SARS-CoV-2 pandemic: concern about ultra-processed food consumption. Foods, 2022, 11(7), 950.
[http://dx.doi.org/10.3390/foods11070950] [PMID: 35407037]
[5]
Castellana, F.; De Nucci, S.; De Pergola, G.; Di Chito, M.; Lisco, G.; Triggiani, V.; Sardone, R.; Zupo, R. Trends in coffee and tea consumption during the covid-19 pandemic. Foods, 2021, 10(10), 2458.
[http://dx.doi.org/10.3390/foods10102458] [PMID: 34681507]
[6]
Moynihan, A.B.; Tilburg, W.A.P.; Igou, E.R.; Wisman, A.; Donnelly, A.E.; Mulcaire, J.B. Eaten up by boredom: consuming food to escape awareness of the bored self. Front. Psychol., 2015, 6, 369.
[http://dx.doi.org/10.3389/fpsyg.2015.00369] [PMID: 25883579]
[7]
Rodríguez-Martín, B.C.; Meule, A. Food craving: new contributions on its assessment, moderators, and consequences. Front. Psychol., 2015, 6, 21.
[http://dx.doi.org/10.3389/fpsyg.2015.00021] [PMID: 25657636]
[8]
Singh, M. Mood, food, and obesity. Front. Psychol., 2014, 5, 925.
[http://dx.doi.org/10.3389/fpsyg.2014.00925] [PMID: 25225489]
[9]
Volpe, S.; Tortorella, C.; Solfrizzi, V.; Piazzolla, G. When inappropriate use of insulin is dangerous: the utility of C-peptide assay in the era of cardioprotective antidiabetic drugs. Diabetes Metab. Syndr. Obes., 2021, 14, 3517-3521.
[http://dx.doi.org/10.2147/DMSO.S321340] [PMID: 34385826]
[10]
Scoccimarro, D.; Giove, G.; Silverii, A.; Dicembrini, I.; Mannucci, E. Effects of home confinement during COVID-19 outbreak on glycemic control in patients with type 2 diabetes receiving telemedicine support. Acta Diabetol., 2022, 59(2), 281-284.
[http://dx.doi.org/10.1007/s00592-021-01817-4] [PMID: 34773181]
[11]
Arsenyadis, F.; Redman, E.; Henson, J.; Brady, E.M.; Coull, N.A.; Khunti, K.; Hall, A.P.; Davies, M.J. Energy intake and weight during the COVID ‐19 lockdown were not altered in a sample of older adults with type 2 diabetes in ENGLAND. Diabetes Obes. Metab., 2022, 24(3), 546-549.
[http://dx.doi.org/10.1111/dom.14585] [PMID: 34704314]
[12]
Biamonte, E.; Pegoraro, F.; Carrone, F.; Facchi, I.; Favacchio, G.; Lania, A.G.; Mazziotti, G.; Mirani, M. Weight change and glycemic control in type 2 diabetes patients during COVID-19 pandemic: the lockdown effect. Endocrine, 2021, 72(3), 604-610.
[http://dx.doi.org/10.1007/s12020-021-02739-5] [PMID: 33950348]
[13]
Vetrani, C.; Calabrese, I.; Di Rienzo, S.; Pagliuca, M.; Rivieccio, A.; De Angelis, R.; Riccardi, G.; Rivellese, A.A.; Annuzzi, G.; Bozzetto, L. Dietary changes during COVID-19 lockdown in adults with type 1 diabetes on a hybrid artificial pancreas. Front. Public Health, 2021, 9752161
[http://dx.doi.org/10.3389/fpubh.2021.752161] [PMID: 34778186]
[14]
Sutkowska, E.; Marciniak, D.M.; Sutkowska, K.; Biernat, K.; Mazurek, J.; Kuciel, N. The impact of lockdown caused by the COVID-19 pandemic on glycemic control in patients with diabetes. Endocrine, 2022, 76(2), 273-281.
[http://dx.doi.org/10.1007/s12020-022-02985-1] [PMID: 35072900]
[15]
Lisco, G.; De Tullio, A.; Giagulli, V.A.; Guastamacchia, E.; De Pergola, G.; Triggiani, V. Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review. Endocrine, 2020, 70(3), 441-453.
[http://dx.doi.org/10.1007/s12020-020-02444-9] [PMID: 32779091]
[16]
Giagulli, V.A.; Guastamacchia, E.; Magrone, T.; Jirillo, E.; Lisco, G.; De Pergola, G.; Triggiani, V. Worse progression of COVID‐19 in men: Is testosterone a key factor? Andrology, 2021, 9(1), 53-64.
[http://dx.doi.org/10.1111/andr.12836] [PMID: 32524732]
[17]
Lisco, G.; Giagulli, V.A.; De Pergola, G.; De Tullio, A.; Guastamacchia, E.; Triggiani, V. COVID-19 in man: A very dangerous affair. Endocr. Metab. Immune Disord. Drug Targets, 2021, 21(9), 1544-1554.
[http://dx.doi.org/10.2174/22123873MTEyAOTQiz] [PMID: 33388025]
[18]
Lisco, G.; De Tullio, A.; Stragapede, A.; Solimando, A.G.; Albanese, F.; Capobianco, M.; Giagulli, V.A.; Guastamacchia, E.; De Pergola, G.; Vacca, A.; Racanelli, V.; Triggiani, V. COVID-19 and the endocrine system: A comprehensive review on the theme. J. Clin. Med., 2021, 10(13), 2920.
[http://dx.doi.org/10.3390/jcm10132920] [PMID: 34209964]
[19]
Lisco, G.; De Tullio, A.; Jirillo, E.; Giagulli, V.A.; De Pergola, G.; Guastamacchia, E.; Triggiani, V. Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. J. Endocrinol. Invest., 2021, 44(9), 1801-1814.
[http://dx.doi.org/10.1007/s40618-021-01554-z] [PMID: 33765288]
[20]
Biancalana, E.; Parolini, F.; Mengozzi, A.; Solini, A. Short-term impact of COVID-19 lockdown on metabolic control of patients with well-controlled type 2 diabetes: a single-centre observational study. Acta Diabetol., 2021, 58(4), 431-436.
[http://dx.doi.org/10.1007/s00592-020-01637-y] [PMID: 33219884]
[21]
Psoma, O.; Papachristoforou, E.; Kountouri, A.; Balampanis, K.; Stergiou, A.; Lambadiari, V.; Liatis, S.; Tsimihodimos, V. Effect of COVID-19-associated lockdown on the metabolic control of patients with type 2 diabetes. J. Diabetes Complications, 2020, 34(12)107756
[http://dx.doi.org/10.1016/j.jdiacomp.2020.107756] [PMID: 33059982]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy